A new paradigm in testing for NSCLC targeted therapies

In the era of personalized medicine, molecular profiling has become essential for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC). With an increasing number of genomic alterations becoming clinically relevant, sequential testing of individual mutations becomes a significant challenge for clinical laboratories. Next-generation sequencing (NGS), which can detect multiple alterations at once from small amount of tissue, offers a solution.

One test that can expedite NSCLC treatment selection decisions

The Ion Torrent Oncomine Dx Target Test is the first targeted NGS-based in vitro diagnostic test for NSCLC, simultaneously delivering multiple biomarker results from one sample within four days.

The Oncomine Dx Target Test has been approved by the FDA as a companion diagnostic to aid in the selection of NSCLC patients for treatment with targeted therapies, including IRESSA® (gefitinib) for EGFR L858R and Exon 19 deletions, Tafinlar + Mekinist® (dabrafenib in combination with trametinib) for BRAF V600E, or XALKORI® (crizotinib) for ROS1 fusion.

The Oncomine Dx Target Test also targets 20 NSCLC-associated gene variants currently investigated in clinical trials that are potentially actionable in the future.

The test will be available starting in July 2017 in the United States. LabCorp, NeoGenomics Laboratories, and Cancer Genetics, Inc., are among the first laboratories that will offer the Oncomine Dx Target Test as a service to oncologists. Availability in other countries will be announced at a later date.

Contact us for more information

For In Vitro Diagnostic Use. Available in the US only.